Why insider trading matters?

When insiders buy shares on the open market, this can thus be regarded as a strong endorsement by those that know the company the best -- they are literally betting their own money on the company's future. Insider selling, however, is not necessarily meaningful in any way, as there is a range of reasons for insiders to liquidate (some) of the shares they own.

- Seeking Alpha
Global Blood Therapeutics, Inc. (GBT)
Sector: Healthcare; Industry: Biotechnology

Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, Oxbryta (voxelotor) tablets, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating Oxbryta that has completed Phase III clinical trial in adult and adolescent patients with SCD. The company has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2019-10-08 PATRICK DEVAL L Director Sell 5,357 $45.05 $241,333 Yes
2019-10-01 SUVARI TRICIA BORGA Chief Legal Officer Sell 3,249 $48.70 $158,226 No
2019-09-11 Calhoun Lesley Ann See Remarks Sell 2,765 $54.36 $150,296 No
2019-02-12 Calhoun Lesley Ann See Remarks Sell 354 $50.45 $17,860 No
2018-08-17 Calhoun Lesley Ann See Remarks Sell 2,004 $49.89 $99,970 Yes
2018-07-06 PATRICK DEVAL L Director Sell 42,379 $43.40 $1,839,283 Yes
2018-07-09 Calhoun Lesley Ann See Remarks Sell 3,295 $44.19 $145,614 Yes
2018-05-17 Choi Jung See Remarks Sell 3,000 $48.25 $144,750 Yes
2018-04-17 Choi Jung See Remarks Sell 3,000 $45.50 $136,500 Yes
2018-03-16 Choi Jung See Remarks Sell 3,000 $54.15 $162,450 Yes
2018-03-05 Calhoun Lesley Ann See Remarks Sell 99 $60.35 $5,975 Yes
2018-02-16 Choi Jung See Remarks Sell 3,000 $62.95 $188,850 Yes
2018-02-01 Radovich Peter See Remarks Sell 812 $57.30 $46,528 Yes
2018-01-23 Radovich Peter See Remarks Sell 30,000 $60.00 $1,800,000 Yes
2018-01-17 Choi Jung See Remarks Sell 3,000 $52.85 $158,550 Yes
2018-01-10 Radovich Peter See Remarks Sell 15,000 $50.00 $750,000 Yes
2017-12-18 Choi Jung See Remarks Sell 3,000 $36.55 $109,650 Yes
2017-12-19 PERCEPTIVE ADVISORS LLC 10%-Owner Buy 175,000 $38.00 $6,650,000 No
2017-11-17 Choi Jung See Remarks Sell 3,000 $39.75 $119,250 Yes
2017-10-30 Radovich Peter Senior VP, Operations Sell 12,500 $35.00 $437,500 No
2017-10-27 HOMCY CHARLES J Director Sell 70,000 $33.97 $2,377,551 No
2017-10-17 Choi Jung See Remarks Sell 3,000 $32.65 $97,950 Yes
2017-09-29 Choi Jung See Remarks Sell 3,000 $30.00 $90,000 Yes
2017-08-31 Radovich Peter See Remarks Sell 2,410 $30.00 $72,300 No
2017-08-31 Choi Jung See Remarks Sell 3,000 $30.00 $90,000 Yes
2017-07-25 PATRICK DEVAL L Director Sell 27,053 $29.69 $803,204 Yes
2017-07-21 Choi Jung See Remarks Sell 3,000 $30.00 $90,000 Yes
2017-06-02 HOMCY CHARLES J Director Sell 100,000 $27.08 $2,708,469 No
2017-04-06 TEPPER ROBERT I 10%-Owner Sell 31,225 $33.23 $1,037,576 No
2017-03-02 Third Rock Ventures II, L.P. 10%-Owner Sell 2,045,294 $25.54 $52,245,476 No

Insider Smart

Edesa Biotech, Inc. (EDSA) - President and CEO bought shares of EDSA in late May around $3, two weeks after their purchase, the stock jump to $9, very well timed buy.

Insider Smart

Enphase Energy, Inc (ENPH) - Watch for CEO Kothandaraman Badrinarayanan and CFO Branderiz Eric, their trading have a good pattern you can't miss, very well timed buy low and sell high.